A Canadian biotech giant is born: AbCellera stock triples in debut, company now worth US$15-billion - The Globe and Mail
BioCentury - AbCellera valuation tops $15B as 2020's IPO class nears completion
DCVC Bio, Viking Global Investors backed AbCellera Biologics files for IPO on NASDAQ - Private Capital Journal
AI drug discovery platform AbCellera prices upsized IPO at $20, above the upwardly revised range - Renaissance Capital
Peter Thiel Is Said to Get Board Seat at AbCellera as IPO Nears - BNN Bloomberg
AbCellera boosts IPO target second time in a week, seeking to raise US$483 - Technology | Business in Vancouver
Pre-IPO: Everything You Need To Know About AbCellera (Part I) (NASDAQ:ABCL) | Seeking Alpha
Pacific Trader: How AbCellera's stock can make a full recovery - BCBusiness
Abcellera Biologics Inc. | BioWorld
IPO: AbCellera Biologics
COVID-19 Antibody Discovery Company Preps for Massive $391 Million IPO | BioSpace
Wish & AbCellera Biologics Inc: Investors' Hawk-eyed On These 2 IPOs | Kalkine Media
IPO Launch: AbCellera Biologics Readies $357 Million IPO - IPOs On TheStreet - U.S. IPO Research & Opinion
IPO Stock AbCellera Eyes Profitability As Covid-19 Antibody Sales Soar | Investor's Business Daily
Vancouver biotech company AbCellera's IPO nets $556M | Venture
Thiel-backed therapy developer AbCellera looks to raise up to $391 million in IPO | Reuters
COVID-19 roundup: AbCellera considering IPO as early as fall - The Logic
AbCellera, tapped by Lilly for its COVID-19 antibody therapy, sets IPO terms with $5B valuation | Fierce Biotech
IPO Alert: AbCellera Biologics (ABCL)
Vancouver's AbCellera on hiring spree after smash IPO | Venture
